Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Mark Mulligan and Vanessa Raabe.
Mark Mulligan
Connection Strength
0.996
Vanessa Raabe
  1. Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2021 Feb; 590(7844):E26.
    View in: PubMed
    Score: 0.232
  2. Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients. Open Forum Infect Dis. 2020 Oct; 7(10):ofaa446.
    View in: PubMed
    Score: 0.226
  3. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 10; 586(7830):589-593.
    View in: PubMed
    Score: 0.224
  4. Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood. Open Forum Infect Dis. 2019 Jan; 6(1):ofy352.
    View in: PubMed
    Score: 0.200
  5. Sequencing identifies multiple early introductions of SARS-CoV-2 to the New York City region. Genome Res. 2020 12; 30(12):1781-1788.
    View in: PubMed
    Score: 0.057
  6. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 12 17; 383(25):2439-2450.
    View in: PubMed
    Score: 0.057
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.